Dianthus Therapeutics, Inc. DNTH
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) is a CNS/neurology/psychiatry drug developer. Its lead program, claseprubart, is in Phase 3 for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its next catalyst on record is claseprubart (MMN): Top-line results from Phase 2 MoMeNtum trial (December 2026).
Upcoming catalysts
- December 2026claseprubart (MMN) — Top-line results from Phase 2 MoMeNtum trial
In August 2026, we announced the completion of enrollment of the MoMeNtum trial, which exceeded its enrollment target of 36 patients, and top-line results with 46 patients are expected in December 2026.
Next further out: DNTH212 — Preliminary data from Phase 1 Part A (healthy volunteers) (Q1 2027). 10 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| claseprubart | CIDP | antibody | Phase 3 |
| claseprubart | generalized Myasthenia Gravis (gMG) | antibody | Phase 3 |
| claseprubart | Multifocal Motor Neuropathy (MMN) | antibody | Phase 2 |
| DNTH212 | Sjögren's Disease, Systemic Lupus Erythematosus, Dermatomyositis | biologic-other | Phase 1 |
| DNTH312 | autoimmune diseases (unspecified) | biologic-other | Pre-clinical |
Recent results and decisions
- Nov 4, 2026positive Interim responder analysis from the first 40 participants in Phase 3 CAPTIVATE Part A showed a 75% response rate, exceeding the target of 50% or greater.
75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial, exceeding the target response rate of 50% or greater based on precedent set with aC1s inhibition.
Filing - started First SLE patient in Part B of the Phase 1 SAD study was dosed in October 2026, with preliminary results expected in second half 2027.
First SLE patient in Part B of the Phase 1 SAD study was dosed in October, with preliminary results from Part B expected in 2H'27.
Filing - Aug 4, 2026positive Interim responder analysis of first 40 participants completing Part A of Phase 3 CAPTIVATE showed a 75% response rate vs a 50% target, generally well tolerated with no related serious infections or SAEs.
75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial, exceeding the target response rate of 50% or greater based on precedent set with aC1s inhibition.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.